New drug NB02 tested for tough lymphoma cases

NCT ID NCT07114367

First seen Feb 01, 2026 · Last updated May 17, 2026 · Updated 14 times

Summary

This early-phase trial tests a new drug called NB02 (posseltinib) in about 9 adults with certain types of Non-Hodgkin lymphoma (follicular, mantle cell, or marginal zone) that have returned or not responded to at least two prior treatments. The main goals are to find a safe dose and check for side effects. Researchers will also look for signs that the drug shrinks tumors.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON HODGKIN LYMPHOMA (NHL) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Catholic univ of Yeouido St Mary's Hospital

    RECRUITING

    Seoul, South Korea

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Chonnam National University Hwasun Hospital

    RECRUITING

    Hwasun, South Korea

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Samsung Medical Center

    RECRUITING

    Seoul, South Korea

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Seoul National University Bundang Hospital

    RECRUITING

    Seongnam, South Korea

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Seoul National University Hospital

    RECRUITING

    Seoul, South Korea

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Ulsan University Hospital

    RECRUITING

    Ulsan, South Korea

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.